Negative symptoms of schizophrenia could explain discrepant data on the association between the 5-HT2A receptor gene and response to antipsychotics

Neuroscience Letters

Volumn 377, Issue 1, 2005, Pages 69-74

  Hamdani, Nora ^a,c   Bonnière, Mickaël ^b   Adès, Jean ^a,c   Hamon, Michel ^c   Boni, Claudette ^c   Gorwood, Philip ^a,c  

^a HÔPITAL LOUIS MOURIER   (France)

^b CENTRE HOSPITALIER RENÉ DUBOS   (France)

^c PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

5 HT2A receptor gene; Negative symptoms; Pharmacogenetics; Refractoriness

Indexed keywords

AMISULPRIDE; CLOZAPINE; NEUROLEPTIC AGENT; OLANZAPINE; RISPERIDONE; SEROTONIN RECEPTOR;

ADULT; ARTICLE; DATA ANALYSIS; DISEASE DURATION; DISEASE SEVERITY; DNA POLYMORPHISM; DRUG EFFICACY; FEMALE; GENDER; GENOTYPE; HOSPITAL DISCHARGE; HUMAN; MAJOR CLINICAL STUDY; MALE; ONSET AGE; PHARMACOGENETICS; PRIORITY JOURNAL; RECEPTOR GENE; SCHIZOPHRENIA; SCORING SYSTEM; SCREENING; SYMPTOM; TREATMENT OUTCOME;

EID: 13844254110     PISSN: 03043940     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neulet.2004.11.070     Document Type: Article

References (44)

1. 2A receptor gene and schizophrenia Schizophr. Res. 67 2004 53 62
2. N. Andreasen Scale for the Assessment of Positive Symptoms (SAPS) 1984 University of Iowa Iowa City, Iowa
3. N. Andreasen Scale for the Assessment of Negative Symptoms (SANS) 1984 University of Iowa Iowa City, Iowa
4. 2A receptor gene Lancet 346 1995 281 282
5. 2A receptor gene and response to clozapine Mol. Psychiatry 3 1998 61 66
6. 2A receptors and clozapine response Schizophr. Res. 32 1998 93 99
7. G. Bartko, E. Frecska, S. Horvath, G. Zador, and M. Arato Predicting neuroleptic response from a combination of multilevel variables in acute schizophrenic patients Acta Psychiatr. Scand. 82 1990 408 412
8. H. Biehl, K. Maurer, E. Jung, and B. Krumm The WHO Psychological Impairments Rating Schedule (WHO/PIRS). II. Impairments in Schizophrenics in cross-sectional and longitudinal perspective - the Mannheim experience in two independent samples Br. J. Psychiatry Suppl. 7 1989 71 77
9. B. Bondy, J. Kuznik, T. Baghai, C. Schule, P. Zwanzger, C. Minov, S. De Jonge, R. Rupprecht, H. Meyer, R.R. Engel, W. Eisenmenger, and M. Ackenheil Lack of association of serotonin-2A receptor gene polymorphism (T102C) with suicidal ideation and suicide Am. J. Med. Genet. 96 2000 831 835
10. T.J. Crow Molecular pathology of schizophrenia: more than one disease process? Br. J. Psychiatry 280 1980 66 68
11. 2A receptor promoter polymorphism, -1438A/G and negative symptom response to olanzapine in schizophrenia Psychopharmacol. Bull. 37 2003 109 112
12. P. Gorwood Genetic association studies in behavioral neuroscience W. Cruzio R. Gerlai Molecular Genetic Techniques for Behavioural Neuroscience 1999 Elsevier Amsterdam 113 121
13. P. Gorwood Clinical assessment in psychiatric genetics M. Leboyer F. Bellivier J.M. Walker Psychiatric Genetics: Methods and Protocols 2003 Humana Press Inc. 99 126
14. 2A receptor gene and bipolar affective disorder Lancet 346 1995 969
15. 2A receptor gene (T102C and 1438G/A) polymorphism in schizophrenia Bull. Clin. Psychopharmacol. 13 2003 161 166
16. D.W. Hosmer, and S. Lemeshow Applied Logistic Regression 1980 J. Wiley New York
17. H.G. Hwu, H. Tan, C.C. Chen, and L.L. Yeh Negative symptoms at discharge and outcome in schizophrenia Br. J. Psychiatry 166 1995 61 67
18. S.R. Kay Significance of the positive-negative distinction in schizophrenia Schizophr. Bull. 16 1990 635 652
19. S.R. Kay, and J.P. Lindenmayer Stability of psychopathology dimensions in chronic schizophrenia: response to clozapine treatment Compr. Psychiatry 32 1991 28 35
20. S.R. Kay, L.A. Opler, and A. Fizbein Significance of positive and negative symptoms in chronic schizophrenia Br. J. Psychiatry 149 1986 439 448
21. R. Keefe, S.G. Silva, D.O. Perkins, and J.A. Lieberman The effects of antipsychotic drugs on neurocognitive impairment in schizophrenia: a review and meta-analysis Schizophr. Bull. 25 1999 201 222
22. B.J. Kinon, J.M. Kane, M. Chakos, and R. Munne Possible predictors of neuroleptic-resistant schizophrenic relapse: influence of negative symptoms and acute extrapyramidal side effects Psychopharmacol. Bull. 29 1993 365 369
23. A. Kipman, L. Bruins-Slot, C. Boni, N. Hanoun, J. Ades, P. Blot, M. Hamon, M. Mouren-Simeoni, and P. Gorwood 5-HT(2A) gene promoter polymorphism as a modifying rather than a vulnerability factor in anorexia nervosa Eur. Psychiatry 17 2002 227 229
24. T. Kolakowska, O. Williams, M. Ardern, M.A. Reveley, K. Jambor, M.G. Gelder, and B.M. Mandelbrote Schizophrenia with good and poor outcome I: early clinical features, response to neuroleptics and signs of organic dysfunction Br. J. Psychiatry 146 1985 229 246
25. P. Kulhara, and K. Chandiramani Positive and negative subtypes of schizophrenia: a follow-up study from India Schizophr. Res. 3 1990 107 116
26. H.Y. Lane, Y.C. Chang, C.C. Chiu, M.L. Chen, M.H. Hsieh, and W.H. Chang Association of risperidone treatment response with a polymorphism in the 5-HT(2A) receptor gene Am. J. Psychiatry 159 2002 1593 1595
27. D.F. Levinson, G.M. Simpson, H. Singh, K. Yadalam, A. Jain, M.J. Stephanos, and P. Silver Fluphenazine dose, clinical response and extra-pyramidal symptoms during acute treatment Arch. Gen. Psychiatry 47 1990 761 768
28. J.A. Lieberman, A.R. Koreen, M. Chakos, B. Sheitman, M. Woerner, J.M. Alvir, and R. Bilder Factors influencing treatment response and outcome of first-episode schizophrenia: implications for understanding the pathophysiology of schizophrenia J. Clin. Psychiatry 57 Suppl. 9 1996 5 9
29. C.H. Lin, S.J. Tsai, Y.W.Y. Yu, H.L. Song, P.C. Tu, C.B. Sim, C.P. Hsu, K.H. Yang, and C.J. Hong No evidence for association of serotonin-2A receptor variant (102T/C) with schizophrenia or clozapine response in a Chinese population Neuroreport 10 1999 57 60
30. P. Mac Guffin, and M. Owen Molecular genetics of schizophrenia: an overview and forward view Eur. Arch. Psychiatr. Clin. Neurosci. 240 1991 169 173
31. 2A receptor and the antipsychotic response to clozapine Am. J. Psychiatry 153 1996 1092 1094
32. J. Marengo, M. Harrow, E.S. Herbener, and J. Sands A prospective longitudinal 10-year study of schizophrenia's three major factors and depression Psychiatry Res. 97 2000 61 77
33. M. Masellis, V. Basile, H.Y. Meltzer, J.A. Lieberman, S. Sevy, F.M. Macciardi, P. Cola, A. Howard, F. Badri, M.M. Nothen, W. Kalow, and J.L. Kennedy Serotonin subtype 2 receptor genes and clinical response to clozapine in schizophrenia patients Neuropsychopharmacology 19 1998 123 132
34. P.R.A. May, S.J. Dencker, J.W. Hubbard, K.K. Midha, and R.P. Liberman A systematic approach to treatment resistance in schizophrenic disorders S.J. Dencker F. Kulhanek Treatment Resistance in Schizophrenia 1988 Vieweg Verlag Braunschweig/Wiesbaden 22 33
35. R.G. McCreadie, D. Wiles, and S. Grant The Scottish first episode schizophrenia study. VII. Two-year follow-up. Scottish Schizophrenia Research Group Acta Psychiatr. Scand. 80 1989 597 602
36. H.Y. Meltzer, S. Matsubara, and J.C. Lee The ratios of serotonin 2 and dopamine 2 affinities differentiate atypical and typical antipsychotic drugs Psychopharmacol. Bull. 25 1989 390 392
37. S. Miller, D. Dykes, and H. Polesky A simple salting out procedure for extracting DNA from human nucleated cells Nucleic Acids Res. 16 1988 1215
38. 2A receptor gene locus: association with schizophrenia or treatment response not detected Psychiatr. Genet. 6 1996 23 27
39. J.I. Nurnberger Jr., M.C. Blehar, C.A. Kaufmann, C. York-Cooler, S.G. Simpson, J. Harkavy-Friedman, J.B. Severe, D. Malaspina, and T. Reich Diagnostic Interview for Genetic studies. Rationale, unique features and training. NIMH genetics initiative Arch. Gen. Psychiatry 51 1994 849 859
40. M.J. Parsons, U.M. D'Souza, M.J. Arranz, R.W. Kerwin, and A.J. Makoff The -1438A/G polymorphism in the 5-hydroxytryptamine type 2A receptor gene affects promoter activity Biol. Psychiatry 56 2004 406 410
41. J. Schumacher, T.G. Schulze, T.F. Wienker, M. Rietschel, and M.M. Nöthen Pharmacogenetics of the clozapine response Lancet 356 2000 506
42. G.N. Simpson, and J.W.S. Angus A rating scale for extrapyramidal side effects Acta Psychiatr. Scand. 212 Suppl. 44 1970 11 19
43. C.A. Tamminga Similarities and differences among antipsychotics J. Clin. Psychiatry 64 Suppl. 17 2003 7 10
44. D.S. Umbricht, W.C. Wirshing, D.A. Wirshing, M. McMeniman, N.R. Schooler, S.R. Marder, and J.M. Kane Clinical predictors of response to clozapine treatment in ambulatory patients with schizophrenia J. Clin. Psychiatry 63 2002 420 424